Helle Nea, Mentula Maarit, Seppälä Tomi, Gissler Mika, Niinimäki Maarit, Heikinheimo Oskari
Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Department of Information and Service Management, Aalto University School of Business, Espoo, Finland.
Acta Obstet Gynecol Scand. 2025 Sep;104(9):1720-1730. doi: 10.1111/aogs.15174. Epub 2025 Jun 9.
The treatment of miscarriage has transformed substantially from surgical to non-surgical. The aim of this study was to evaluate the rates of adverse events related to the treatment of miscarriage and their risk factors.
This nationwide retrospective cohort study included 69 593 fertile-aged (15-49 years) women who experienced their first miscarriage during 1998-2016 and received a diagnostic code of missed abortion or blighted ovum in a public hospital. We used data from the Finnish National Hospital Discharge Registry (NHDR). Miscarriage type, treatment modalities, and treatment-related adverse events (secondary surgery for any reason, infection and severe adverse events) were identified using diagnostic and surgical procedure codes.
Since 2004, non-surgical management has been the dominant treatment of miscarriage in Finland. Between 1998 and 2016, a total of 11 397 women (16.4%) experienced at least one miscarriage treatment-related adverse event. The need for secondary surgery was the most common adverse event and more common after primary non-surgical treatment (22.0% vs. 3.8%). However, the annual rate of secondary surgery after non-surgical treatment declined from 34.8% in 1998 to 15.9% in 2016. The total number of women undergoing surgical treatment (primary or secondary) declined from 3918 (84.6%) to 651 (23.1%). Age was associated with an increased risk of secondary surgery (age ≥ 25; Adjusted odds ratio [AdjOR] 1.15, 95% CI 1.07-1.24) and with a decreased overall risk of infection (age 40-49 years; AdjOR 0.51 [0.40-0.63]). Parity was associated with lower risk of secondary surgery (one delivery, AdjOR 0.82 [0.78-0.95], and ≥2 deliveries, AdjOR 0.75, [0.71-0.84]) and infection (one delivery, AdjOR 0.85, [0.77-0.95]; ≥2 deliveries, AdjOR 0.74 [0.66-0.84]). Severe adverse events were rare (0.2%-0.4%) and did not differ between the two treatment options for either type of miscarriage.
Despite significant changes in miscarriage treatment practices, no substantial or alarming increase in treatment-associated adverse events was detected. Both treatment options proved safe for the two types of miscarriage studied. These findings are important regarding the provision of individualized counseling and for the allocation of healthcare resources.
流产的治疗方式已从手术治疗大幅转变为非手术治疗。本研究的目的是评估与流产治疗相关的不良事件发生率及其风险因素。
这项全国性回顾性队列研究纳入了69593名育龄期(15 - 49岁)女性,她们在1998年至2016年间经历了首次流产,并在公立医院获得稽留流产或枯萎卵的诊断编码。我们使用了芬兰国家医院出院登记处(NHDR)的数据。通过诊断和手术操作编码确定流产类型、治疗方式以及与治疗相关的不良事件(因任何原因进行的二次手术、感染和严重不良事件)。
自2004年以来,非手术治疗一直是芬兰流产的主要治疗方式。1998年至2016年间,共有11397名女性(16.4%)经历了至少一次与流产治疗相关的不良事件。二次手术的需求是最常见的不良事件,在初次非手术治疗后更为常见(22.0%对3.8%)。然而,非手术治疗后二次手术的年发生率从1998年的34.8%降至2016年的15.9%。接受手术治疗(初次或二次)的女性总数从3918人(84.6%)降至651人(23.1%)。年龄与二次手术风险增加相关(年龄≥25岁;调整优势比[AdjOR] 1.15,95%置信区间1.07 - 1.24),与总体感染风险降低相关(年龄40 - 49岁;AdjOR 0.51 [0.40 - 0.63])。产次与二次手术风险降低相关(一次分娩,AdjOR 0.82 [0.78 - 0.95],≥2次分娩,AdjOR 0.75,[0.71 - 0.84])和感染风险降低相关(一次分娩,AdjOR 0.85,[0.77 - 0.95];≥2次分娩,AdjOR 0.74 [0.66 - 0.84])。严重不良事件很少见(0.2% - 0.4%),两种流产类型的两种治疗方式之间无差异。
尽管流产治疗方法发生了重大变化,但未检测到与治疗相关的不良事件有实质性或令人担忧的增加。对于所研究的两种流产类型,两种治疗方式均被证明是安全的。这些发现对于提供个性化咨询和医疗资源分配具有重要意义。